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Abstract Cyclic di-GMP (c-di-GMP) is an almost universal bacterial second messenger
involved in the regulation of cell surface-associated traits and the persistence of infections.
GGDEF and EAL domain-containing proteins catalyse c-di-GMP synthesis and degradation,
respectively. We report the enzymatic large-scale synthesis of c-di-GMP, making use of the
GGDEF domain-containing protein YdeH from Escherichia coli. Overexpression and
purification of YdeH have been established, and the conditions for c-di-GMP synthesis were
optimised. In contrast to the chemical synthesis of c-di-GMP, enzymatic c-di-GMP production
is a one-step reaction that can easily be performedwith the equipment of a standard biochemical
lab. The protocol allows the production of milligram amounts of c-di-GMP within 1 day and
paves the way for extensive biochemical and biophysical studies on c-di-GMP-mediated
processes.
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Introduction
Bis-(3′-5′)-cyclic di-GMP (c-di-GMP) is an important bacterial second messenger involved
in the regulation of a number of complex physiological processes. C-di-GMP was first
identified 20 years ago as an activating factor of cellulose synthase in Acetobacter xylinum
[1], but in the mean time, it has been shown to play a central role, among others, in the transition
between a motile, single-cell state to a sessile, surface-attached state found in biofilms [2–5]. Its
relevance for the virulence of pathogenic bacteria is well established [2–6].
C-di-GMP is synthesised by the condensation of two GTP molecules. This reaction is
catalysed by the GGDEF domain of diguanylate cyclases (DGCs) [7–10], whereas EAL
[7, 11–13] and HD-GYP [14] domains hydrolyse the compound to yield the linear pGpG
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dinucleotide. All these catalytic domains are typically found in combinations with other,
mostly sensory or regulatory, domains and control the cellular level of c-di-GMP.
Much about the mechanisms of c-di-GMP signalling in bacteria has still to be
discovered, in particular since only a few targets of c-di-GMP have been identified.
Characterised c-di-GMP receptors comprise PilZ domains [15] and degenerated GGDEF
and EAL domains [16, 17]. Furthermore, the GEMM riboswitches have recently been
discovered to regulate gene expression via c-di-GMP binding [18–20].
Recent studies have demonstrated that exogenous c-di-GMP treatment inhibits adhesive
Staphylococcus aureus cell-to-cell interactions and biofilm formation [21] and that it is
effective also in a mouse model [22]. These findings make c-di-GMP an interesting
candidate as a potential antimicrobial agent. It was demonstrated that c-di-GMP stimulates
the immune system to prevent bacterial infections and is therefore evaluated as a potential
vaccine adjuvant candidate [23–25]. It was also reported that c-di-GMP inhibits cancer cell
proliferation in vitro and could therefore be used as a therapeutic agent [26].
In order to carry out extensive studies on c-di-GMP-mediated processes, sufficient
supply of this compound is crucial. The reported chemical syntheses of c-di-GMP are
multistep reactions, which make them time-consuming, expensive and inefficient [27–33].
Most of them make use of phosphotriester, phosphoamidite or H-phosphonate chemistry based
on air- or water-sensitive reagents and involve several chromatographic purification steps.
In contrast, DGC-catalysed synthesis of c-di-GMP from GTP appears straightforward, as
has been reported for PleD, VCA0956 and WspR [12, 13, 34–37]. However, all these
DGCs show potent allosteric product inhibition with Ki values in the low micromolar range.
Furthermore, the purified proteins are rather unstable in solution. Recently, a DGC from a
thermophilic organism (Thermotoga maritima) has been employed for the enzymatic
synthesis of c-di-GMP [38]. A fragment comprising only its DGC domain with the
allosteric inhibition site (I-site) mutated to impede product inhibition has been exploited.
Large amounts (about 20 mg) of c-di-GMP were obtained employing 1 mg of this modified
version of the enzyme and by replenishing repeatedly the reaction mixture with the
substrate GTP.
In this paper, we report a large-scale production procedure of c-di-GMP employing, as
an alternative enzyme, YdeH from Escherichia coli. This enzyme consists of an N-terminal
domain of unknown fold and a C-terminal GGDEF domain. We have shown previously
[39] that YdeH, in contrast to most of the other DGCs, is a constitutively active dimer and
exhibits a turnover of 1.6 min−1 and a Km of 17 μM. The YdeH catalysed reaction shows
non-competitive product inhibition only at comparatively large c-di-GMP concentration
(Ki=44 μM), in contrast to the aforementioned DGCs. Furthermore, even at very high
c-di-GMP concentration (>1 mM), YdeH shows residual activity (15%) [39]. We show
that with this enzyme, complete conversion of GTP to c-di-GMP can be achieved within
hours, yielding milligram amount of product.
Material and Methods
Expression and Purification of YdeH
C-terminally His6-tagged YdeH was expressed in the pET28b plasmid in the E. coli Rosetta
strain. The transformed cells were cultivated at 37 °C in Luria–Bertani medium supplemented
with ampicillin (100 μg/mL) and chloramphenicol (34 μg/mL) until the OD600 had reached
0.7. Gene expression was induced by adding 1 mM isopropyl-β-D-thiogalactopyranoside
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(IPTG). After 4 h of incubation, the cells were harvested by centrifugation (6,800×g, 10 min,
4 °C) and the pellets were frozen at −20 °C.
Prior to lysis, the frozen cell pellets were thawed and resuspended in Ni-A buffer
(50 mM NaH2PO4, pH 7.5, 200 mM NaCl, 10 mM imidazole, 50 mM L-glutamic acid,
50 mM L-arginine). After the addition of DNAse (2.5 μg/mL; Sigma) and EDTA-free
protease-inhibitor cocktail (Roche, 1 tablet/50 mL buffer), the cells were disrupted with a
French press (Thermo Spectronic) at 15,000 psi. The lysate was cleared by centrifugation
(28,000×g, 45 min, 4 °C), and the supernatant was filtered (0.22 μm) and loaded onto a 5-mL
HisTrap column (GE Healthcare). After washing the column with Ni-A buffer (10 column
volumes (CV)), the protein was eluted with a linear gradient of imidazole from 10 to
500 mM in 10 CV. The pooled fractions were concentrated to 1 mL and further purified
by size-exclusion chromatography using a Superdex 75 16/60 column (GE Healthcare)
and SEC buffer (20 mM Tris–HCl, pH 7.6, 150 mM NaCl, 50 mM L-glutamic acid,
50 mM L-arginine). The chromatographic runs were carried out with an Äkta Purifier
FPLC unit and monitored with Unicorn software. The purification process was monitored
by SDS-PAGE followed by Coomassie blue R-250 staining. Protein concentration was
determined by measuring the absorbance at 280 nm (ε280=39,880 M
−1cm−1).
Enzyme Assay
The initial rate of c-di-GMP synthesis was measured by following the substrate
consumption using ion exchange chromatography. The reaction mixture (100 μL) contained
2 μM purified YdeH, 100 μM GTP (Sigma), and 5 mM MgCl2. The effect of pH on the
activity of YdeH was tested in 50 mM MES, pH 6.5–7.5, 50 mM Tris–HCl, pH 7.5–8.5,
and 50 mM CHES, pH 9.0–10.0. Also, the effect of different salts (LiCl, NaCl and KCl)
and NaCl concentrations (25 mM–1.5 M) was investigated. The reaction was stopped by
heating of the sample for 2 min at 99 °C. Subsequently, 100 μL of the reaction mixture was
diluted in 900 μL 5 mM NH4HCO3, pH 8.0, filtered (0.22 μm) and loaded on an ion-
exchange column (ResourceQ 1 mL, GE Healthcare). The nucleotides were separated with
a gradient from 0.005 to 1 M NH4HCO3, pH 8.0, in 14 CV. The amount of substrate and
reaction product was determined by integration of the UV absorption (253 nm) peaks. The
procedure was calibrated with GTP (Sigma) and c-di-GMP (Biolog, Bremen) standards of
known concentrations.
Enzymatic Production of c-di-GMP
For the synthesis of c-di-GMP, 2 μM YdeH was incubated with 500 μM GTP in 50 mM
Tris–HCl, pH 7.5, 50 mM NaCl and 5 mM MgCl2 for 5 h. The progress of the reaction was
followed by withdrawing samples (100 μL) that were inactivated by heat denaturation.
Subsequently, the enzyme was removed by filtering and the sample content analysed by
ion-exchange chromatography. After completion of the reaction, the mixture was heated for
5 min at 99 °C, centrifuged (4,500×g, 10 min, room temperature) and filtered (0.22 μm).
For purification of the reaction product, Et3NHCO3 to a final concentration of 5 mM was
added to the reaction mixture and loaded on a reversed-phase chromatography column
(1.7 mL per 1 mL resin Resource RPC, GE Healthcare). After washing the column with
5 mM Et3NHCO3 (10 CV), c-di-GMP was eluted with a linear gradient of ethanol from 0%
to 50% in 10 CV. The reversed-phase chromatography was carried out with an Äkta Purifier
FPLC unit and monitored with Unicorn software. The c-di-GMP-containing fractions were
pooled and lyophilised. The powder was dissolved in water and the concentration was
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determined by measuring the optical density at 253 nm of an aliquot diluted to 10 μM
(assuming an ε253 of 23,700 M
−1cm−1 as reported in [29]).
Analytical Methods
Purified c-di-GMP was analysed by high-performance liquid chromatography coupled to
mass spectrometry. The samples were diluted 50-fold with 10 mM NH4OAc, pH 6.4, and
injected into a SupercosilTM LC-18-T column (Supelco). The run was performed at a flow
rate of 0.7 mL/min using a linear gradient (0–50%) of acetonitrile. The electron spray
ionisation mass spectrometry with a time-of-flight analyser was performed using a
microTOF Focus system (Bruker Daltronics). The capillary voltage was 4500 V, and the
end-plate offset was 500 V (negative mode); the dry temperature was 200 °C, the dry gas
flow was 9 L/min, and the nebulizer pressure was 2 bar.
To test the purity of the obtained c-di-GMP, a sample was analysed by 1H-nuclear
magnetic resonance (NMR) spectroscopy (Bruker Advance 600) in 10 mM Tris–HCl
(D11), pH 7.4 (Cambridge Isotope Laboratories, Inc.), 150 mM NaCl, 50 μM EDTA at
298 K. For comparison, spectra of synthetic c-di-GMP (Biolog) and GTP (Sigma) were
acquired.
Results and Discussion
Expression and Purification of YdeH
YdeH expression was tested in different E. coli strains and at different temperatures. In all
conditions, most of the expressed YdeH was found in inclusion bodies. The highest amount
of soluble protein was achieved in the Rosetta strain at 37 °C, 3–4 h after IPTG induction.
YdeH was purified to homogeneity using a two-step purification procedure, consisting of
Ni-affinity and size-exclusion chromatography. To achieve a protein concentration above
0.8 mg/mL, the addition of arginine and glutamic acid to the buffers was essential to avoid
protein aggregation [40]. The obtained protein was pure and no degradation fragments were
present, as demonstrated by the occurrence of a single band on SDS-PAGE (Fig. 1). The
final yield was about 5 mgL−1 culture.
Optimisation and Characterisation of the Enzymatic Reaction
Substrate and product amounts were analysed by ion-exchange chromatography. A peak at
a somewhat smaller elution volume than that of the final product was observed in the
Fig. 1 SDS-PAGE of the
purification of YdeH. A 12%
(w/v) gel loaded with: lane 1
molecular weight marker, lane 2
cell extract, lane 3 soluble
fraction of the cell extract, lane 4
purified YdeH after Ni column,
lane 5 purified YdeH after
size-exclusion chromatography
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chromatograms taken at early to intermediate time points, but was absent after completion
of the reaction (Fig. 2). As demonstrated by MS, this transient peak did not correspond to a
reaction intermediate, but had the mass of c-di-GMP. Probably, the two peaks correspond to
different oligomeric states of c-di-GMP.
The optimum pH for the synthesis of c-di-GMP was found to be at pH 7.5 in Tris buffer
(Fig. 3). Variation of the salt (LiCl, NaCl, KCl) had only a marginal effect. The enzymatic
activity was virtually the same in 50 mM NaCl and 50 mM KCl, but was found to be
reduced by about 20% in 50 mM LiCl. Similarly, variation of the NaCl concentration
(25 mM–1.5 M) had no significant effect on activity. Therefore, we chose a comparatively
low NaCl concentration (50 mM) to be compatible with the requirements for the subsequent
c-di-GMP purification procedure.
Enzymatic c-di-GMP Production and Purification
For the large-scale synthesis of c-di-GMP, the molar ratio of enzyme to substrate has been
optimised in order to obtain complete conversion within a convenient period. Using 2 μM
YdeH and 500 μM GTP, virtually complete substrate conversion was achieved within 5 h,
Fig. 2 Time course of the
synthesis of c-di-GMP. The
samples were analysed using
ion-exchange chromatography.
After 5 h, the reaction is virtually
complete. The leftmost small and
constant peak corresponds to a
GDP contamination in the
commercial GTP batch
Fig. 3 pH dependence of the
enzymatic activity of YdeH.
The optimum reaction velocity
for the synthesis of c-di-GMP
was found in 50 mM Tris–HCl,
pH 7.5
Appl Biochem Biotechnol (2011) 163:71–79 75
as shown in Fig. 2. Initially, the reaction volume was 0.1 mL, but was eventually upscaled
to 0.5 L without any detrimental effect. C-di-GMP was purified on a reversed-phase
column with ethanol as eluent. The Resource RPC resin was chosen because of its
stability at basic pH values. The mobile phase was adjusted so as to prevent binding of the
mono-nucleotides GDP and GTP. Ethanol has the advantage of being non-toxic compared
to other typically used eluents such as acetonitrile or methanol. The procedure yielded
75 mg of pure c-di-GMP employing 30 mg of YdeH. Considering the ease of YdeH
purification, further optimisation of the procedure by recycling of the enzyme as in [38]
was not considered.
Product Analysis
LC/MS clearly identified the reaction product as c-di-GMP (Fig. 4). No impurities were
detected in the chromatogram. The observed mass of c-di-GMP was in perfect agreement
with the calculated mass. In addition, the 1H-NMR spectra of purified c-di-GMP
completely coincided with the spectrum of chemically synthesised c-di-GMP and showed
no traces of the substrate GTP (Fig. 5).
Conclusions
Here, we have described an alternative way for the enzymatic synthesis of the bacterial
second messenger c-di-GMP. We use the DGC YdeH from E. coli, which is an ideal
Fig. 4 Convoluted mass spectrum of enzymatically produced c-di-GMP. The measured mass of 690.1775 g/
mol is in agreement with the calculated mass of 690.0870 g/mol
Fig. 5 Part of the 1H-NMR
spectrum (600 MHz) showing
the chemical shift of H8 of
enzymatically produced
c-di-GMP (top, δ=8.04) and of
GTP (bottom, δ=8.13) as
reference. Comparison demon-
strates that the c-di-GMP sample
was free of GTP. Chemical shifts
are relative to H2O (δ=4.77,
298 K)
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candidate because it is constitutively active in vitro and exhibits only weak product
inhibition; thus, c-di-GMP concentrations of up to 0.25 mM can be achieved. Our system
allows producing 2.5 mg of pure c-di-GMP per milligram of YdeH with standard
biochemical lab equipment.
Enzymatic c-di-GMP production outperforms chemical synthesis with respect to time,
costs and number of chromatographic purification steps [27–33]. Moreover, most of the
chemical syntheses are based on air- and water-sensitive reagents. The enzymatic
procedures described in the literature [12, 13, 34–37], however, employ rather unstable
DGCs that, in addition, show strong product inhibition and therefore do not yield complete
substrate conversion. The recently described procedure using a DGC from a thermophilic
organism (T. maritima) [38] solved the solubility issue and provides the best specific yield
so far (20 mg/mg enzyme), but had to be mutated in the allosteric inhibition site (I-site) to
abolish product inhibition.
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